What Will Happen to Jazz Pharmaceuticals Plc – Ordinary Shares (NASDAQ:JAZZ) Next? The Stock Has Increase in Shorts

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Logo

Investors sentiment decreased to 1.17 in 2019 Q2. Its down 0.32, from 1.49 in 2019Q1. It turned negative, as 36 investors sold Jazz Pharmaceuticals plc shares while 105 reduced holdings. 52 funds opened positions while 113 raised stakes. 50.63 million shares or 4.18% more from 48.59 million shares in 2019Q1 were reported.
Apg Asset Nv reported 0% stake. Nelson Van Denburg Campbell Wealth Mgmt Gp Lc reported 630 shares or 0.02% of all its holdings. Winslow Evans & Crocker stated it has 106 shares or 0% of all its holdings. Globeflex Cap Limited Partnership has 5,960 shares. The Minnesota-based Stonebridge Cap Advsr Limited Com has invested 0.01% in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Captrust Financial has 0% invested in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Caisse De Depot Et Placement Du Quebec holds 0% of its portfolio in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) for 11,500 shares. Smith Asset Mngmt Group L P accumulated 153,970 shares or 0.73% of the stock. Assetmark Incorporated stated it has 0% in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). 341,297 were reported by Martingale Asset Management L P. Royal Savings Bank Of Canada holds 174,730 shares or 0.01% of its portfolio. Brown Mgmt Ltd Co reported 0.01% in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Next Gp Inc accumulated 1,200 shares. Verition Fund Mngmt Ltd Liability Company has invested 0.05% in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). The Nebraska-based Cwm Limited has invested 0% in Jazz Pharmaceuticals plc (NASDAQ:JAZZ).

The stock of Jazz Pharmaceuticals Plc – Ordinary Shares (NASDAQ:JAZZ) registered an increase of 10.97% in short interest. JAZZ’s total short interest was 2.24 million shares in September as published by FINRA. Its up 10.97% from 2.02 million shares, reported previously. With 499,000 shares average volume, it will take short sellers 5 days to cover their JAZZ’s short positions. The short interest to Jazz Pharmaceuticals Plc – Ordinary Shares’s float is 4.08%.

The stock decreased 0.03% or $0.04 during the last trading session, reaching $131.41. About 330,700 shares traded. Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has declined 19.23% since September 13, 2018 and is downtrending. It has underperformed by 19.23% the S&P500.

Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has market cap of $7.44 billion. The firm has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. It has a 11.92 P/E ratio. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Ratings Coverage

Among 8 analysts covering Jazz Pharmaceuticals (NASDAQ:JAZZ), 6 have Buy rating, 0 Sell and 2 Hold. Therefore 75% are positive. Jazz Pharmaceuticals has $20800 highest and $14200 lowest target. $168.25’s average target is 28.03% above currents $131.41 stock price. Jazz Pharmaceuticals had 8 analyst reports since March 18, 2019 according to SRatingsIntel. The rating was maintained by Mizuho on Wednesday, May 8 with “Neutral”. RBC Capital Markets maintained the stock with “Buy” rating in Monday, March 18 report. The stock of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has “Outperform” rating given on Wednesday, May 8 by BMO Capital Markets. SunTrust initiated the stock with “Buy” rating in Tuesday, March 19 report. Wells Fargo maintained Jazz Pharmaceuticals plc (NASDAQ:JAZZ) rating on Tuesday, March 19. Wells Fargo has “Buy” rating and $162 target. The company was maintained on Thursday, March 21 by Oppenheimer. The firm has “Neutral” rating given on Wednesday, August 21 by Piper Jaffray.

More notable recent Jazz Pharmaceuticals plc (NASDAQ:JAZZ) news were published by: Seekingalpha.com which released: “Piper softens view on Jazz Pharma in premarket analyst action – Seeking Alpha” on August 21, 2019, also Bioworld.com with their article: “Harmony wins FDA approval for narcolepsy drug Wakix – BioWorld Online” published on August 16, 2019, Nasdaq.com published: “Why Is Jazz (JAZZ) Down 7.3% Since Last Earnings Report? – Nasdaq” on June 06, 2019. More interesting news about Jazz Pharmaceuticals plc (NASDAQ:JAZZ) were released by: Nasdaq.com and their article: “Jazz Pharmaceuticals (JAZZ) Reports Next Week: Wall Street Expects Earnings Growth – Nasdaq” published on April 30, 2019 as well as Seekingalpha.com‘s news article titled: “FDA OKs competitor to Jazz Pharma’s Xyrem – Seeking Alpha” with publication date: August 15, 2019.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.